High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer
- 30 November 1987
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 23 (12) , 1895-1900
- https://doi.org/10.1016/0277-5379(87)90056-3
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Oral high‐dose medroxyprogesterone acetate versus tamoxifen: A randomized crossover trial in postmenopausal patients with advanced breast cancerCancer, 1986
- A phase III trial of oral high-dose medroxyprogesterone acetate (MPA) versus mepitiostane in advanced postmenopausal breast cancerCancer, 1985
- Oral medroxyprogesterone acetate in the treatment of metastatic breast cancerBreast Cancer Research and Treatment, 1985
- Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancerCancer Chemotherapy and Pharmacology, 1985
- An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancerBritish Journal of Cancer, 1984
- High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapyCancer Chemotherapy and Pharmacology, 1979
- Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancerPublished by Elsevier ,1979
- Assessment of response to therapy in advanced breast cancer.A project of the programme on clinical oncology of the International Union against Cancer, Geneva, SwitzerlandCancer, 1977
- Treatment of Breast Cancer with Medroxyprogesterone AcetateAnnals of Internal Medicine, 1968
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958